JP2024177569A5 - - Google Patents

Info

Publication number
JP2024177569A5
JP2024177569A5 JP2024178238A JP2024178238A JP2024177569A5 JP 2024177569 A5 JP2024177569 A5 JP 2024177569A5 JP 2024178238 A JP2024178238 A JP 2024178238A JP 2024178238 A JP2024178238 A JP 2024178238A JP 2024177569 A5 JP2024177569 A5 JP 2024177569A5
Authority
JP
Japan
Prior art keywords
crystalline form
peaks
composition
crystalline
ttr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024178238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024177569A (ja
Filing date
Publication date
Priority claimed from JP2019545281A external-priority patent/JP7157752B2/ja
Application filed filed Critical
Publication of JP2024177569A publication Critical patent/JP2024177569A/ja
Publication of JP2024177569A5 publication Critical patent/JP2024177569A5/ja
Pending legal-status Critical Current

Links

JP2024178238A 2017-02-17 2024-10-10 Ag-10、その中間体及びその塩の調製方法 Pending JP2024177569A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762460576P 2017-02-17 2017-02-17
US62/460,576 2017-02-17
JP2019545281A JP7157752B2 (ja) 2017-02-17 2018-02-16 Ag-10、その中間体及びその塩の調製方法
PCT/US2018/000025 WO2018151815A1 (en) 2017-02-17 2018-02-16 Processes for preparing ag-10, its intermediates, and salts thereof
JP2022162530A JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022162530A Division JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法

Publications (2)

Publication Number Publication Date
JP2024177569A JP2024177569A (ja) 2024-12-19
JP2024177569A5 true JP2024177569A5 (https=) 2025-11-28

Family

ID=63166944

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019545281A Active JP7157752B2 (ja) 2017-02-17 2018-02-16 Ag-10、その中間体及びその塩の調製方法
JP2022162530A Pending JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法
JP2024178238A Pending JP2024177569A (ja) 2017-02-17 2024-10-10 Ag-10、その中間体及びその塩の調製方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019545281A Active JP7157752B2 (ja) 2017-02-17 2018-02-16 Ag-10、その中間体及びその塩の調製方法
JP2022162530A Pending JP2022183220A (ja) 2017-02-17 2022-10-07 Ag-10、その中間体及びその塩の調製方法

Country Status (17)

Country Link
US (5) US10513497B2 (https=)
EP (1) EP3582773A4 (https=)
JP (3) JP7157752B2 (https=)
KR (3) KR102874295B1 (https=)
CN (3) CN116730920A (https=)
AU (2) AU2018222739C1 (https=)
CA (1) CA3051357A1 (https=)
CL (1) CL2019002321A1 (https=)
EA (1) EA201991921A1 (https=)
IL (3) IL268683B2 (https=)
MA (1) MA47511A (https=)
MX (3) MX2021015220A (https=)
NZ (2) NZ755597A (https=)
SG (1) SG11201906922TA (https=)
TW (3) TWI791487B (https=)
WO (1) WO2018151815A1 (https=)
ZA (1) ZA202407964B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116730920A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
TWI817999B (zh) 2018-03-23 2023-10-11 美商文涵治療有限公司 使用ag10治療ttr澱粉樣沉積症之方法
SI3836920T1 (sl) 2018-08-17 2026-02-27 Eidos Therapeutics, Inc. Formulacije AG10
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
WO2023009612A1 (en) 2021-07-28 2023-02-02 Protego Biopharma, Inc. Acoramidis (3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid) derivatives for stabilizing transthyretin (tts) and inhibiting tts misfolding for the treatment of e.g. peripheral ttr amyloidosis
WO2023052652A1 (en) 2021-10-01 2023-04-06 Sandoz Ag Crystalline form of acoramidis hydrochloride
WO2025220043A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Solid state forms of acoramidis and process for their preparation
WO2026050334A1 (en) 2024-08-29 2026-03-05 Alexion Pharmaceuticals, Inc. Transthyretin stabilizers and methods of use thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
AU668818B2 (en) 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
JP2000508339A (ja) 1996-10-01 2000-07-04 シーマ・ラブス・インコーポレイテッド 味隠蔽マイクロカプセル組成物及び製造方法
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2004096808A1 (en) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Triazine compounds and their use
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
EP1919288A4 (en) 2005-07-18 2009-12-16 Horizon Therapeutics Inc FAMOTIDINE- AND IBUPROGEN-BASED MEDICAMENTS AND THEIR ADMINISTRATION
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 n-(메틸)-1h-피라졸-3-아민, n-(메틸)-피리딘-2-아민 및 n-(메틸)-티아졸-2-아민 유도체
US20130012485A1 (en) 2006-12-22 2013-01-10 Baeschlin Daniel Kaspar Organic compounds
ES2395872T3 (es) 2007-05-11 2013-02-15 Eli Lilly And Company 2-[4-(Pirazol-4-ilalquil)piperazin-1-il]-3-fenil pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor de 5-HT7
EP2167464B1 (en) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
HRP20100611T1 (hr) 2007-06-06 2010-12-31 Torrent Pharmaceuticals Ltd Novi spojevi
MX2009013213A (es) 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GEP20125708B (en) 2008-03-26 2012-12-10 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
MX360460B (es) 2008-10-20 2018-11-05 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion de transtiretina.
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
CN103370326B (zh) 2010-12-16 2016-05-11 阿勒根公司 作为趋化因子受体调节剂的磷衍生物
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2016025129A1 (en) * 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
PT4070788T (pt) 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN116730920A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
TWI817999B (zh) 2018-03-23 2023-10-11 美商文涵治療有限公司 使用ag10治療ttr澱粉樣沉積症之方法
SI3836920T1 (sl) 2018-08-17 2026-02-27 Eidos Therapeutics, Inc. Formulacije AG10

Similar Documents

Publication Publication Date Title
JP2024177569A5 (https=)
JP2022183220A5 (https=)
JPWO2022138988A5 (https=)
JP2021185200A5 (https=)
JP2024105460A5 (https=)
JP2024071370A5 (https=)
JP2023082086A5 (https=)
JP2021536511A5 (https=)
JP2020128376A5 (https=)
JP2014524442A5 (https=)
JP2010516681A5 (https=)
JP2009521414A5 (https=)
JP2012067131A5 (https=)
JP2009541220A5 (https=)
JP2020512350A5 (https=)
JP2015145426A5 (https=)
JP2021513975A5 (https=)
HRP20171201T1 (hr) Postupak kristalizacije i biodostupnost
PE20251749A1 (es) Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos
PT2773620T (pt) Cloridrato de ivabradina de forma iv
ZA200204285B (en) Heterocyclo-alkylsulfonyl pyrazole derivatives as antiinflammatory/analgesic agents.
JP2024547113A5 (https=)
JP2025502064A5 (https=)
JP2023530785A5 (https=)
JP2025142197A5 (https=)